Q-omics provides the consensus-scored FBXL18 profile across patient tissues and cancer cell-line models. FBXL18 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FBXL18 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, FBXL18 RNA expression shows 19,905 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where FBXL18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL18 survival associations across molecular data types. FBXL18 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL18 RNA expression–survival associations across cancer types. High FBXL18 expression shows unfavorable associations in CESC, BLCA, ACC, LIHC, THCA and MESO. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for FBXL18 RNA expression.
This table summarizes FBXL18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXL18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL18 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LIHC, LUAD and LUSC. The HNSC box plot shows higher FBXL18 RNA expression in tumor versus normal tissue (log2 FC = +0.904, t-test p < 0.001).
This table shows molecular features associated with FBXL18 in patient tissues and cancer cell lines. In patient samples, FBXL18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
